Medicare Has Expanded Access to GLP-1 Medications: What You Need to Know

For years, Medicare generally did not cover medications when they were prescribed solely for weight loss. As GLP-1 medications became more widely used, one of the biggest frustrations we've heard from Medicare beneficiaries was the cost, particularly for people whose prescription drug plans would not cover treatment for weight management.

That's what makes the new Medicare GLP-1 Bridge such an important change. Beginning July 1, 2026, Medicare introduced the temporary GLP-1 Bridge program to help eligible beneficiaries access select GLP-1 medications at a predictable monthly cost. The program is available nationwide, including in all states and U.S. territories.

While the program does not cover every GLP-1 medication or apply to everyone with Medicare, it creates a new option for beneficiaries who meet the medical and coverage requirements.

Who May Be Eligible?

The Medicare GLP-1 Bridge is available to people who are at least 18 years old, have Medicare prescription drug coverage, and meet the program's clinical requirements.

Medicare drug coverage. You must have Part D coverage through a standalone prescription drug plan, a qualifying Medicare Advantage plan with drug coverage, a Special Needs Plan, certain employer or union plans, or the LI NET program.

A BMI of 35 or higher. Beneficiaries with a body mass index of at least 35 may qualify without one of the additional health conditions required at lower BMI levels.

A BMI of 30 or higher with an additional health condition. Qualifying conditions include diastolic heart failure (heart failure with preserved ejection fraction), uncontrolled high blood pressure, or chronic kidney disease at stage 3a or higher.

A BMI of 27 or higher with certain cardiovascular or metabolic risks. These include prediabetes, a previous heart attack or stroke, or symptomatic peripheral artery disease affecting the arms or legs.

A healthcare provider must prescribe one of the medications included in the program and complete a prior authorization when requested. The provider must also certify that the medication is being used as part of a lifestyle program focused on diet and exercise.

Some beneficiaries will not qualify for the Bridge because their GLP-1 medication is already covered through their regular Part D benefit. People with type 2 diabetes, moderate-to-severe obstructive sleep apnea, or certain fatty liver disease indications may already be eligible for GLP-1 coverage through their existing prescription drug plan.

Which Medications Are Included?

The Medicare GLP-1 Bridge currently includes three medications for weight reduction and long-term weight management.

Foundayo® – available as a tablet

Wegovy® – available as an injection or tablet

Zepbound® – currently limited to the KwikPen® formulation

The program does not cover Zepbound single-dose vials or single-dose pens. Because the list of covered medications may change during the demonstration, it's a good idea to confirm that your prescribed medication and formulation are included before beginning treatment.

What Will It Cost?

One of the biggest advantages of the Medicare GLP-1 Bridge is its predictable cost. Eligible beneficiaries pay a $50 copayment for each 28- or 30-day supply obtained through the program. Sixty- and 90-day prescriptions are not available through the Bridge.

It's also important to understand how the program works alongside your existing Medicare prescription drug coverage. Because the GLP-1 Bridge operates separately from your regular Part D benefit, the $50 copayment does not count toward your Part D deductible or annual out-of-pocket spending limit. It also won't appear on your Medicare Explanation of Benefits or qualify for programs like Extra Help or the Medicare Prescription Payment Plan.

Is This a Permanent Medicare Benefit?

Not at this time.

The Medicare GLP-1 Bridge is a temporary demonstration program scheduled to remain in place through December 31, 2027. Demonstration programs allow Medicare to evaluate new approaches to care while collecting data on patient outcomes, treatment utilization, and long-term healthcare costs before deciding whether broader policy changes should be considered.

While there is no guarantee this program will become a permanent Medicare benefit, it reflects Medicare's growing recognition that GLP-1 medications may play an important role in improving health outcomes for certain beneficiaries.

What This Means for You

If cost has kept you from considering a GLP-1 medication for weight management, now may be a good time to revisit the conversation with your healthcare provider. Eligibility depends on your Medicare prescription drug coverage, your BMI, your health history, and whether your provider believes one of the covered medications is appropriate for your treatment.

Even if Medicare didn't cover these medications when you looked into them previously, this new program has created opportunities that simply weren't available before.

As always, we'll continue monitoring Medicare updates and sharing the changes that matter most. Medicare continues to evolve, and staying informed can help you make confident decisions about your healthcare and prescription drug coverage.